Insights
Why We Invested in Celerion: Advancing the Future of Clinical Pharmacology
Key Takeaways: In April 2026, THL announced a majority investment in Celerion, a global leader in clinical pharmacology and bioanalytical sciences that supports pharmaceutical and biotechnology companies in advancing new therapies through critical stages of clinical development. As drug development becomes increasingly complex — driven by novel therapeutic modalities, precision medicine, and evolving regulatory requirements — clinical
Healthcare (HC)